arrow
M

Matthew Wongchenko

free university of berlin
H指数:34
被引数:6,970

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Reply to Felix Melchior, Andreas Pircher, and Isabel Heidegger’s Letter to the Editor re: Johann S. de Bono, Meng He, Chen Shi, et al. Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. Eur Urol. 2025;87:468–75

回复Felix Melchior、Andreas Pircher和Isabel Heidegger致编辑的信:关于Johann S. de Bono、Meng He、Chen Shi等人。第3阶段IPATential150试验中接受Ipatasertib和Abiraterone治疗患者的最终总生存期及与临床结局相关的分子数据。欧洲泌尿外科杂志。2025;87:468–75。

2025-04-100
PRE
MiRaDor: A proof-of- concept study of treatment efficacy by monitoring Minimal Residual Disease (MRD) using circulating tumor DNA (ctDNA) in hormone receptor-positive/HER2-negative (HR+/HER2-) early breast cancer (EBC)
2024-05-020
PRE
Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer

自噬基因Atg16l1的肿瘤内在表达抑制结直肠癌的抗肿瘤免疫

2023-09-2310
OAAI
Tumour gene expression signature in primary melanoma predicts long-term outcomes (vol 12, 1137, 2021)

原发性黑色素瘤中的肿瘤基因表达特征预测长期结果 (第12卷,1137,2021)

2022-05-170
OAAI
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial
2021-12-0356
OAAI
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer

一线ipatasertib加紫杉醇治疗不能手术的局部晚期/转移性三阴性乳腺癌的双盲安慰剂对照随机2期LOTUS试验的最终结果

2021-07-1554
PREAI
Tumour gene expression signature in primary melanoma predicts long-term outcomes

原发性黑色素瘤的肿瘤基因表达特征预测长期结果

2021-02-1847
OAAI
IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)
2020-09-0131
OAAI
Expression of PD-L1 is independent of PIK3CA/AKT1/PTEN alterations in triple-negative breast cancer (TNBC) and is not associated with response to ipatasertib (IPAT) plus paclitaxel (PAC)
2020-02-152
PRE
Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC)

Ib期研究评估ipatasertib (IPAT),atezolizumab (atezo) 和紫杉醇 (PAC) 或nab-pac的三联组合作为局部晚期/转移性三阴性乳腺癌 (TNBC) 的一线 (1L) 治疗

2019-07-0135
PRE